Secondary distribution of HIV self-test kits by HIV index and antenatal care clients: implementation and costing results from the STAR Initiative in South Africa.
HIV index clients
HIV self-testing
Linkage to care
Men
Secondary distribution
South Africa
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
01 Jun 2023
01 Jun 2023
Historique:
received:
16
05
2022
accepted:
11
05
2023
medline:
5
6
2023
pubmed:
2
6
2023
entrez:
1
6
2023
Statut:
epublish
Résumé
Partner-delivered HIV self-testing kits has previously been highlighted as a safe, acceptable and effective approach to reach men. However, less is known about its real-world implementation in reaching partners of people living with HIV. We evaluated programmatic implementation of partner-delivered self-testing through antenatal care (ANC) attendees and people newly diagnosed with HIV by assessing use, positivity, linkage and cost per kit distributed. Between April 2018 and December 2019, antenatal care (ANC) clinic attendees and people or those newly diagnosed with HIV clients across twelve clinics in three cities in South Africa were given HIVST kits (OraQuick Rapid HIV-1/2 Antibody Test, OraSure Technologies) to distribute to their sexual partners. A follow-up telephonic survey was administered to all prior consenting clients who were successfully reached by telephone to assess primary outcomes. Incremental economic costs of the implementation were estimated from the provider's perspective. Fourteen thousand four hundred seventy-three HIVST kits were distributed - 10,319 (71%) to ANC clients for their male partner and 29% to people newly diagnosed with HIV for their partners. Of the 4,235 ANC clients successfully followed-up, 82.1% (3,475) reportedly offered HIVST kits to their male partner with 98.1% (3,409) accepting and 97.6% (3,328) using the kit. Among ANC partners self-testing, 159 (4.8%) reported reactive HIVST results, of which 127 (79.9%) received further testing; 116 (91.3%) were diagnosed with HIV and 114 (98.3%) initiated antiretroviral therapy (ART). Of the 1,649 people newly diagnosed with HIV successfully followed-up; 1,312 (79.6%) reportedly offered HIVST kits to their partners with 95.8% (1,257) of the partners accepting and 95.9% (1,206) reported that their partners used the kit. Among these index partners, 297 (24.6%) reported reactive HIVST results of which 261 (87.9%) received further testing; 260 (99.6%) were diagnosed with HIV and 258 (99.2%) initiated ART. The average cost per HIVST distributed in the three cities was US$7.90, US$11.98, and US$14.81, respectively. Partner-delivered HIVST in real world implementation was able to affordably reach many male partners of ANC attendees and index partners of people newly diagnosed with HIV in South Africa. Given recent COVID-19 related restrictions, partner-delivered HIVST provides an important strategy to maintain essential testing services.
Sections du résumé
BACKGROUND
BACKGROUND
Partner-delivered HIV self-testing kits has previously been highlighted as a safe, acceptable and effective approach to reach men. However, less is known about its real-world implementation in reaching partners of people living with HIV. We evaluated programmatic implementation of partner-delivered self-testing through antenatal care (ANC) attendees and people newly diagnosed with HIV by assessing use, positivity, linkage and cost per kit distributed.
METHODS
METHODS
Between April 2018 and December 2019, antenatal care (ANC) clinic attendees and people or those newly diagnosed with HIV clients across twelve clinics in three cities in South Africa were given HIVST kits (OraQuick Rapid HIV-1/2 Antibody Test, OraSure Technologies) to distribute to their sexual partners. A follow-up telephonic survey was administered to all prior consenting clients who were successfully reached by telephone to assess primary outcomes. Incremental economic costs of the implementation were estimated from the provider's perspective.
RESULTS
RESULTS
Fourteen thousand four hundred seventy-three HIVST kits were distributed - 10,319 (71%) to ANC clients for their male partner and 29% to people newly diagnosed with HIV for their partners. Of the 4,235 ANC clients successfully followed-up, 82.1% (3,475) reportedly offered HIVST kits to their male partner with 98.1% (3,409) accepting and 97.6% (3,328) using the kit. Among ANC partners self-testing, 159 (4.8%) reported reactive HIVST results, of which 127 (79.9%) received further testing; 116 (91.3%) were diagnosed with HIV and 114 (98.3%) initiated antiretroviral therapy (ART). Of the 1,649 people newly diagnosed with HIV successfully followed-up; 1,312 (79.6%) reportedly offered HIVST kits to their partners with 95.8% (1,257) of the partners accepting and 95.9% (1,206) reported that their partners used the kit. Among these index partners, 297 (24.6%) reported reactive HIVST results of which 261 (87.9%) received further testing; 260 (99.6%) were diagnosed with HIV and 258 (99.2%) initiated ART. The average cost per HIVST distributed in the three cities was US$7.90, US$11.98, and US$14.81, respectively.
CONCLUSIONS
CONCLUSIONS
Partner-delivered HIVST in real world implementation was able to affordably reach many male partners of ANC attendees and index partners of people newly diagnosed with HIV in South Africa. Given recent COVID-19 related restrictions, partner-delivered HIVST provides an important strategy to maintain essential testing services.
Identifiants
pubmed: 37264343
doi: 10.1186/s12879-023-08324-7
pii: 10.1186/s12879-023-08324-7
pmc: PMC10234581
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
971Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Informations de copyright
© 2023. The Author(s).
Références
Afr J AIDS Res. 2019 Dec;18(4):332-340
pubmed: 31779576
Front Public Health. 2021 Feb 19;9:594298
pubmed: 33681120
Lancet HIV. 2021 May;8(5):e284-e293
pubmed: 33667411
J Acquir Immune Defic Syndr. 2018 Dec 1;79(4):467-473
pubmed: 30148731
PLoS One. 2020 May 22;15(5):e0233606
pubmed: 32442226
J Womens Health (Larchmt). 2008 Jan-Feb;17(1):47-55
pubmed: 18240981
PLoS One. 2018 Aug 27;13(8):e0202521
pubmed: 30148846
J Acquir Immune Defic Syndr. 2020 Aug 1;84(4):355-364
pubmed: 32195749
J Acquir Immune Defic Syndr. 2020 Jul 1;84(3):271-279
pubmed: 32168168
J Int AIDS Soc. 2019 Mar;22 Suppl 1:e25255
pubmed: 30907499
BMC Public Health. 2020 Jan 15;20(1):66
pubmed: 31941479
AIDS. 2015 Jul 17;29(11):1401-9
pubmed: 26091299
J Int AIDS Soc. 2019 Mar;22 Suppl 1:e25244
pubmed: 30907505
Trop Med Int Health. 2017 Jul;22(7):807-821
pubmed: 28449385
J Int AIDS Soc. 2020 Jun;23 Suppl 2:e25514
pubmed: 32589337
Public Health. 2017 Feb;143:1-7
pubmed: 28159020
South Afr J HIV Med. 2017 Sep 22;18(1):775
pubmed: 29568643
PLoS Med. 2019 Jan 2;16(1):e1002719
pubmed: 30601823
PLoS One. 2018 Nov 29;13(11):e0208191
pubmed: 30496260
BMJ Open. 2021 May 18;11(5):e048585
pubmed: 34006558
J Int AIDS Soc. 2019 Mar;22 Suppl 1:e25249
pubmed: 30907517
J Int AIDS Soc. 2011 Nov 03;14:52
pubmed: 22050673
HIV AIDS (Auckl). 2013 May 29;5:111-9
pubmed: 23766660
J Int AIDS Soc. 2017 Jun 26;20(1):21610
pubmed: 28691442